Physician profile
Paul A Nguyen
NPI 1740497346
$14,047.25
in general payments reported to CMS, 2019-2025
23 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 88% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $613 · 2021: $2,321 · 2022: $2,942 · 2023: $3,004 · 2024: $2,028 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Education: $7.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.70 |
| Education | $7.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,865.81 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,510.20 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $2,509.64 | 2021-2025 | |
| Alkermes, INC. | $1,239.23 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $951.07 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $759.34 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $463.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $443.71 | 2020-2024 | Invega Sustenna |
| Allergan, INC. | $398.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $391.86 | 2020-2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $348.62 | 2019-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $252.24 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $204.74 | 2021-2023 | Rexulti |
| Axsome Therapeutics, INC. | $150.21 | 2023 | Auvelity |
| Eisai INC. | $145.77 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $140.13 | 2022-2023 | Aplenzin |
| Indivior INC. | $109.03 | 2021-2023 | Perseris, Sublocade |
| Idorsia Pharmaceuticals US INC | $39.72 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $35.61 | 2024 | |
| Avion Pharmaceuticals | $30.36 | 2023 | Methylphenidate Hydrochloride |
| Neuronetics, INC. | $29.73 | 2023 | Neurostar Tms Therapy System |
| Corium, LLC | $20.39 | 2023 | Azstarys |
| Sumitomo Pharma America, INC. | $7.83 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.